The Oncology InstituteSTLN
Recorded

The Oncology Institute 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration37 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please note that this call is being recorded, and I will be standing by should you need any assistance. It is now my pleasure to turn the meeting over to Minh Merchant.

Minh MerchantChief Legal Officer

Please go ahead. Thank you, operator, and good afternoon, everyone.

Minh MerchantChief Legal Officer

Welcome to Starling Oncology's third quarter 2026 earnings conference call. I am Minh Merchant, Chief Legal Officer, and joining me today are Dan Virnich, our Chief Executive Officer, and Rob Carter, our Chief Financial Officer. The press release announcing our results for the third quarter of 2026 is available in the investor relations section of our website, starlingoncology.com. A replay of this call will also be available on our website following its conclusion. Before we get started, I would like to remind you of the company's safe harbor language included on our press release for the third quarter of 2026. Management may make forward-looking statements, including guidance and underlying assumptions. These forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially.

Minh MerchantChief Legal Officer

For a further discussion of risks related to our business, please see our filings with the SEC, including our most recent Form 10-K and subsequent Form 10-Qs. This call will also discuss non-GAAP financial measures, such as Adjusted EBITDA, MLR, and free cash flow. A reconciliation of these non-GAAP measures to the most comparable GAAP measures is included in the earnings release furnished to the SEC and available on our website. With that, I will turn the call over to Dan.

Daniel VirnichCEO

Thank you, Min. Good afternoon, everyone, and thank you for joining our third quarter 2026 earnings call. I am excited to report that we delivered another quarter of record revenue of $159.8 million, an increase of 24% year-over-year, and Adjusted EBITDA of $3.4 million, meaningfully above the top end of the Q3 range we provided on our last call. This is our second consecutive quarter of positive Adjusted EBITDA, and we are reaffirming full-year Adjusted EBITDA positivity in 2026. In addition to our strong financial performance, we have a number of positive updates today on our performance, including growth in capitated relationships, performance of our pharmacy, as well as strong data on utilization management effectiveness we are seeing from Starling Nexus, our recently launched provider portal.

Daniel VirnichCEO

We continue to make meaningful progress in what is a pivotal year for our company as we look for profitability, realize operating leverage from our growth and growing scale, and stabilize our balance sheet. Let me start with an update on Starling Nexus, our proprietary utilization management portal that we announced the launch of in early August. Starling Nexus is now live for our network providers who practice in all markets where we have delegated capitation arrangements and is the interface through which prior authorizations are submitted for UM review. This currently includes contracts previously announced on prior calls in Florida, as well as our first delegated capitation contract outside of Florida, which went effective October 1, 2026, the health plan in Oregon, where we have a statewide contract for Medicare Advantage with approximately 40,000 incremental lives.

Daniel VirnichCEO

We are encouraged by early data on how effective Nexus will be for implementation of our UM program for non-employed providers. Currently, over 300 network practices have the ability to access the platform, and we are seeing over half of first-pass submission adherence to our therapeutic pathways with over 90% formulary adherence on authorizations which require substitution after initial review. In addition, our data shows we are implementing highly compliant and fast UM operations at scale, with over 99.2% compliance on over 4,000 authorizations in Florida this year alone, and an average UM decision time of 13 hours after submission, which is incredibly fast by health plan standards and aligns with our mission to provide better access to care for the populations that we serve.

Daniel VirnichCEO

A major strategic goal of Starling Nexus in upcoming years is to increase access to ancillary services for our network providers to drive value for the patients they manage, as well as help grow revenue and profitability from these important services for our investors. As noted on our last call, we are now live with the first ancillary service enhancement, which is access to Part D electronic prescribing in the portal for practices that wish to select Starling as pharmacy of choice. We will be engaging with network practices to help drive awareness of this fast and convenient service in Q4. This will be an incremental growth channel for our Part D business going forward. Other services on the roadmap for integration in the upcoming year include centralized clinical trials access and care navigation. Stepping back from Nexus, I also want to call out the performance of our capitated business overall.

Daniel VirnichCEO

Capitated revenue grew 40% year-over-year in the third quarter, and our medical loss ratio, or MLR, improved sequentially to 81% from 85.5% in the second quarter, slightly better than we had anticipated. We believe this is yet another proof point of our ability to effectively manage oncology cost of care at scale for our patients and payer partners. Turning to our Part D specialty pharmacy business, continued increase in capture rate of fills written by Starling physicians was the primary contributor to year-over-year revenue growth in the specialty pharmacy, as the team has implemented technology and human capital-driven workflows to operationalize the ease and benefit of Starling providers and patients utilizing our captive pharmacy for their specialty medication needs.

Daniel VirnichCEO

Additionally, Starling is seeing more new patients for treatment planning services, particularly as a result of growth in capitated lives pursuant to new contract ramp, which is driving first-time fills into our pharmacy as we deliver on our customer service model and overall value proposition of specialty pharmacy as a core part of our integrated care model. Revenue from Part D in the third quarter was $109 million, up 44% year-over-year, and gross margin was an incredible 24%. We are in a unique position to manage drug margin through our scaled procurement, robust internal analytics on pricing, and active utilization management efforts. Rob will provide more detail on these efforts in a few minutes. While this was an exceptional quarter for Part D margins, we expect margins to likely normalize in the high teens percent range long term.

Daniel VirnichCEO

Turning to our pipeline of new contracts, we have a number of positives to highlight. Capitated revenue and capitated lives are both up year-over-year, 40% and 10% respectively, driven by the growth we've experienced in both our narrow and delegated relationships across states. on October 1st, we celebrated a milestone for Starling by starting our first delegated capitation contract outside of Florida in our Oregon market through a statewide health plan relationship covering their approximately 40,000 Medicare Advantage lives. In Florida, we now have a fully contracted statewide provider network ready to serve any payer that we partner with, and we have several additional opportunities in our pipeline with new health plan partners as we look to 2027.

Daniel VirnichCEO

We continue to serve three anchor health plan partners through delegated capitation across five counties as of this call, and for reasons unrelated to Starling performance, will not be immediately expanding statewide with these partners. Looking forward, we continue to anticipate capitated revenue growth of 100% in 2027 versus 2026, and known addressable opportunities in our current 2027 pipeline exceed $1 billion in annualized spend, including several high-quality opportunities outside of our current five states. While we will not execute on 100% of the addressable pipeline, it highlights the increasing demand for our services and ongoing scalability of Starling over the next several years, while mitigating customer concentration within any one market or health plan partner. To wrap up, in our third quarter, we exceeded our guidance on Adjusted EBITDA and set new records for total revenue and Part D growth for our business.

Daniel VirnichCEO

We expanded our delegated capitation model to a new state while continuing to reduce MLR towards the lower end of our guided range, and we are well-positioned to deliver on full-year Adjusted EBITDA positivity for 2026 within our prior guidance. We are seeing tremendous early results from Nexus in terms of network provider performance on formulary adherence, and we are just starting to tap into other ancillary service opportunities in the network. The integration of ePrescribe that will position this platform well to drive tremendous value for Starling and our investors in the upcoming years. With that, I'll turn the call over to Rob to discuss our financials in more detail.

Rob CarterCFO

Rob? Thanks, Dan, and good afternoon, everyone.

Rob CarterCFO

On the call today, I will review our third quarter financial results, touch on our balance sheet and cash flow, and close with our guidance and outlook. Total revenue for the third quarter was $169.8 million, compared to $136.6 million in the prior year period, representing 24.3% year-over-year growth. Patient services revenue, which includes both our capitated and fee-for-service arrangements, was $60 million, representing 35.4% of total revenue. Within patient services, capitated revenue increased 39.5% year over year to $28.7 million, while fee-for-service revenue decreased 21% to $31.3 million. I would like to provide additional context on the decline in fee-for-service. While our platform continues to grow organically, as demonstrated by a 9% increase in underlying visit volumes from the prior year third quarter, we have experienced a shift in segment economics.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day